$65.39
+2.37 (+3.76%)
Open$64.06
Previous Close$63.02
Day High$66.01
Day Low$64.00
52W High$68.39
52W Low$15.32
Volume—
Avg Volume646.1K
Market Cap1.79B
P/E Ratio—
EPS$-0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-20.8% upside
Current
$65.39
$65.39
Target
$51.79
$51.79
$39.42
$51.79 avg
$66.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 232.20M | 82.73M | 183.45M |
| Net Income | -13,095,830 | -118,469,876 | 2.09M |
| Profit Margin | -5.6% | -151.2% | 1.1% |
| EBITDA | -25,741,946 | -141,571,926 | 3.06M |
| Free Cash Flow | — | — | 1.04M |
| Rev Growth | +183.6% | +13.1% | +5.3% |
| Debt/Equity | 7.43 | 4.99 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |